The impact of hedgehog signaling pathway on DNA repair mechanisms in human cancer

Cancers

Volumn 7, Issue 3, 2015, Pages 1333-1348

  Meng, Erhong ^a   Hanna, Ann ^a   Samant, Rajeev S ^a   Shevde, Lalita A ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Cancer; DNA repair; Drug resistance; Hedgehog

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; OSTEOPONTIN; PROTEIN PATCHED 1; REPLICATION FACTOR A; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSFORMING GROWTH FACTOR BETA; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER STEMNESS; CARCINOGENESIS; CELL PROTECTION; CELL SURVIVAL; DIRECT REPAIR; DISEASE ASSOCIATION; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; DNA REPLICATION; DOWN REGULATION; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; EXCISION REPAIR; GENE EXPRESSION REGULATION; HUMAN; METASTASIS; MISMATCH REPAIR; MOLECULAR DYNAMICS; MULTIDRUG RESISTANCE; NEOPLASM; NONHUMAN; ONCOLOGICAL PARAMETERS; PANCREAS ADENOCARCINOMA; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECOMBINATION REPAIR; REVIEW; SIGNAL TRANSDUCTION; SINGLE STRANDED DNA BREAK; TUMOR INVASION; UPREGULATION;

EID: 84938545219     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7030839     Document Type: Review

References (98)

1. Hansen, W.K.; Kelley, M.R. Review of mammalian DNA repair and translational implications. J. Pharmacol. Exp. 2000, 295, 1–9.
2. Khanna, A. DNA Damage in Cancer Therapeutics: A Boon or a Curse? Cancer Res. 2015, 75, 2133–2138. [CrossRef] [PubMed]
3. Tian, H.; Gao, Z.; Li, H.; Zhang, B.; Wang, G.; Zhang, Q.; Pei, D.; Zheng, J. DNA damage response–a double-edged sword in cancer prevention and cancer therapy. Cancer Lett. 2015, 358, 8–16. [CrossRef] [PubMed]
4. Lahtz, C.; Pfeifer, G.P. Epigenetic changes of DNA repair genes in cancer. Journal of molecular cell. Biology 2011, 3, 51–58.
5. Woll, P.S.; Morris, J.K.; Painschab, M.S.; Marcus, R.K.; Kohn, A.D.; Biechele, T.L.; Moon, R.T.; Kaufman, D.S. Wnt signaling promotes hematoendothelial cell development from human embryonic stem cells. Blood 2008, 111, 122–131. [CrossRef] [PubMed]
6. Takahashi-Yanaga, F.; Kahn, M. Targeting Wnt signaling: Can we safely eradicate cancer stem cells? Clin. Cancer Res. 2010, 16, 3153–3162. [CrossRef] [PubMed]
7. Merchant, A.; Joseph, G.; Wang, Q.; Brennan, S.; Matsui, W. Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors. Blood 2010, 115, 2391–2396. [CrossRef] [PubMed]
8. Merchant, A.A.; Matsui, W. Targeting Hedgehog—A cancer stem cell pathway. Clin. Cancer Res. 2010, 16, 3130–3140. [CrossRef] [PubMed]
9. Varnat, F.; Duquet, A.; Malerba, M.; Zbinden, M.; Mas, C.; Gervaz, P.; Ruiz i Altaba, A. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol. Med. 2009, 1, 338–351. [CrossRef] [PubMed]
10. Syn, W.K.; Jung, Y.; Omenetti, A.; Abdelmalek, M.; Guy, C.D.; Yang, L.; Wang, J.; Witek, R.P.; Fearing, C.M.; Pereira, T.A et al. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009, 137, 1478–1488. [CrossRef] [PubMed]
11. Malizia, A.P.; Lacey, N.; Walls, D.; Egan, J.J.; Doran, P.P. CUX1/Wnt signaling regulates epithelial mesenchymal transition in EBV infected epithelial cells. Exp. Cell Res. 2009, 315, 1819–1831. [CrossRef] [PubMed]
12. Ingham, P.W.; McMahon, A.P. Hedgehog signaling in animal development: Paradigms and principles. Genes. Dev. 2001, 15, 3059–3087. [CrossRef] [PubMed]
13. Nusslein-Volhard, C.; Wieschaus, E. Mutations affecting segment number and polarity in Drosophila. Nature 1980, 287, 795–801. [CrossRef] [PubMed]
14. Hui, C.C.; Angers, S. Gli proteins in development and disease. Annu. Rev. Cell Dev. Biol. 2011, 27, 513–537. [CrossRef] [PubMed]
15. Sasaki, H.; Nishizaki, Y.; Hui, C.; Nakafuku, M.; Kondoh, H. Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: Implication of Gli2 and Gli3 as primary mediators of Shh signaling. Development 1999, 126, 3915–3924. [PubMed]
16. Hassounah, N.B.; Bunch, T.A.; McDermott, K.M. Molecular pathways: The role of primary cilia in cancer progression and therapeutics with a focus on Hedgehog signaling. Clin. Cancer Res. 2012, 18, 2429–2435. [CrossRef] [PubMed]
17. Rohatgi, R.; Milenkovic, L.; Corcoran, R.B.; Scott, M.P. Hedgehog signal transduction by Smoothened: Pharmacologic evidence for a 2-step activation process. Proc. Natl. Acad. Sci. USA 2009, 106, 3196–3201. [CrossRef] [PubMed]
18. McMillan, R.; Matsui, W. Molecular pathways: The hedgehog signaling pathway in cancer. Clin. Cancer Res. 2012, 18, 4883–4888. [CrossRef] [PubMed]
19. Carpenter, R.L.; Lo, H.W. Hedgehog pathway and GLI1 isoforms in human cancer. Discovery Med. 2012, 13, 105–113.
20. Shevde, L.A.; Samant, R.S. Non-classical hedgehog-GLI signaling and its clinical implications. Int. J. Cancer 2014, 135, 1–6. [CrossRef] [PubMed]
21. Das, S.; Samant, R.S.; Shevde, L.A. Nonclassical activation of hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to Smoothened-targeting hedgehog inhibition. J. Biol. Chem. 2013, 288, 11824–11833. [CrossRef] [PubMed]
22. Harris, L.G.; Samant, R.S.; Shevde, L.A. Hedgehog signaling: Networking to nurture a promalignant tumor microenvironment. Mol. Cancer Res. 2011, 9, 1165–1174. [CrossRef] [PubMed]
23. Petrova, E.; Rios-Esteves, J.; Ouerfelli, O.; Glickman, J.F.; Resh, M.D. Inhibitors of Hedgehog acyltransferase block Sonic Hedgehog signaling. Nat. Chem. Biol. 2013, 9, 247–249. [CrossRef] [PubMed]
24. Mas, C.; Ruiz, I.; Altaba, A. Small molecule modulation of HH-GLI signaling: Current leads, trials and tribulations. Biochem. Pharmacol. 2010, 80, 712–723. [CrossRef] [PubMed]
25. Martin, S.A.; Lord, C.J.; Ashworth, A. Therapeutic targeting of the DNA mismatch repair pathway. Clin. Cancer Res. 2010, 16, 5107–5113. [CrossRef] [PubMed]
26. Kinsella, T.J. Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. Clin. Cancer Res. 2009, 15, 1853–1859. [CrossRef] [PubMed]
27. Prolla, T.A.; Baker, S.M.; Harris, A.C.; Tsao, J.L.; Yao, X.; Bronner, C.E.; Zheng, B.; Gordon, M.; Reneker, J.; Arnheim, N et al. Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair. Nat. Genet. 1998, 18, 276–279. [CrossRef] [PubMed]
28. Li, G.M.; Modrich, P. Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MutL homologs. Proc. Natl. Acad. Sci. USA 1995, 92, 1950–1954. [CrossRef] [PubMed]
29. Plotz, G.; Raedle, J.; Brieger, A.; Trojan, J.; Zeuzem, S. N-terminus of hMLH1 confers interaction of hMutLalpha and hMutLbeta with hMutSalpha. Nucleic Acids Res. 2003, 31, 3217–3226. [CrossRef] [PubMed]
30. Shah, S.N.; Hile, S.E.; Eckert, K.A. Defective mismatch repair, microsatellite mutation bias, and variability in clinical cancer phenotypes. Cancer Res. 2010, 70, 431–435. [CrossRef] [PubMed]
31. Mazumdar, T.; DeVecchio, J.; Agyeman, A.; Shi, T.; Houghton, J.A. The GLI genes as the molecular switch in disrupting Hedgehog signaling in colon cancer. Oncotarget 2011, 2, 638–645. [PubMed]
32. Shao, H.; Baitinger, C.; Soderblom, E.J.; Burdett, V.; Modrich, P. Hydrolytic function of Exo1 in mammalian mismatch repair. Nucleic Acids Res. 2014, 42, 7104–7112. [CrossRef] [PubMed]
33. Inaguma, S.; Riku, M.; Hashimoto, M.; Murakami, H.; Saga, S.; Ikeda, H.; Kasai, K. GLI1 interferes with the DNA mismatch repair system in pancreatic cancer through BHLHE41-mediated suppression of MLH1. Cancer Res. 2013, 73, 7313–7323. [CrossRef] [PubMed]
34. Wogan, G.N.; Hecht, S.S.; Felton, J.S.; Conney, A.H.; Loeb, L.A. Environmental and chemical carcinogenesis. Semin. Cancer Biol. 2004, 14, 473–486. [CrossRef] [PubMed]
35. Brooks, P.J. The case for 8,5’-cyclopurine-2’-deoxynucleosides as endogenous DNA lesions that cause neurodegeneration in xeroderma pigmentosum. Neuroscience 2007, 145, 1407–1417. [CrossRef] [PubMed]
36. Johnson, K.A.; Fink, S.P.; Marnett, L.J. Repair of propanodeoxyguanosine by nucleotide excision repair in vivo and in vitro. J. Biol. Chem. 1997, 272, 11434–11438. [PubMed]
37. Ariza, R.R.; Keyse, S.M.; Moggs, J.G.; Wood, R.D. Reversible protein phosphorylation modulates nucleotide excision repair of damaged DNA by human cell extracts. Nucleic Acids Res. 1996, 24, 433–440. [CrossRef] [PubMed]
38. Moggs, J.G.; Yarema, K.J.; Essigmann, J.M.; Wood, R.D. Analysis of incision sites produced by human cell extracts and purified proteins during nucleotide excision repair of a 1,3-intrastrand d(GpTpG)-cisplatin adduct. J. Biol. Chem. 1996, 271, 7177–7186. [PubMed]
39. Lindahl, T.; Barnes, D.E.; Klungland, A.; Mackenney, V.J.; Schar, P. Repair and processing events at DNA ends. Ciba Found. Symp. 1997, 211, 198–205. [PubMed]
40. Lindahl, T.; Karran, P.; Wood, R.D. DNA excision repair pathways. Curr. Opin. Genet. Dev. 1997, 7, 158–169. [CrossRef]
41. He, Z.; Henricksen, L.A.; Wold, M.S.; Ingles, C.J. RPA involvement in the damage-recognition and incision steps of nucleotide excision repair. Nature 1995, 374, 566–569. [CrossRef] [PubMed]
42. Hosokawa, M.; Takehara, A.; Matsuda, K.; Eguchi, H.; Ohigashi, H.; Ishikawa, O.; Shinomura, Y.; Imai, K.; Nakamura, Y.; Nakagawa, H. Oncogenic role of KIAA0101 interacting with proliferating cell nuclear antigen in pancreatic cancer. Cancer Res. 2007, 67, 2568–2576. [CrossRef] [PubMed]
43. Kudo, K.; Gavin, E.; Das, S.; Amable, L.; Shevde, L.A.; Reed, E. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair. Oncogene 2012, 31, 4718–4724. [CrossRef] [PubMed]
44. Kreklau, E.L.; Limp-Foster, M.; Liu, N.; Xu, Y.; Kelley, M.R.; Erickson, L.C. A novel fluorometric oligonucleotide assay to measure O(6)-methylguanine DNA methyltransferase, methylpurine DNA glycosylase, 8-oxoguanine DNA glycosylase and abasic endonuclease activities: DNA repair status in human breast carcinoma cells overexpressing methylpurine DNA glycosylase. Nucleic Acids Res. 2001, 29, 2558–2566. [PubMed]
45. Marathi, U.K.; Dolan, M.E.; Erickson, L.C. Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2’-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity. Cancer Res. 1994, 54, 4371–4375. [PubMed]
46. Erickson, L.C. The role of O-6 methylguanine DNA methyltransferase (MGMT) in drug resistance and strategies for its inhibition. Semin. Cancer Biol. 1991, 2, 257–265. [PubMed]
47. Pieper, R.O.; Futscher, B.W.; Dong, Q.; Ellis, T.M.; Erickson, L.C. Comparison of O-6-methylguanine DNA methyltransferase (MGMT) mRNA levels in Mer+ and Mer-human tumor cell lines containing the MGMT gene by the polymerase chain reaction technique. Cancer Commun. 1990, 2, 13–20. [PubMed]
48. Cui, D.; Xu, Q.; Wang, K.; Che, X. Gli1 is a potential target for alleviating multidrug resistance of gliomas. J. Neurol. Sci. 2010, 288, 156–166. [CrossRef] [PubMed]
49. Yoon, J.W.; Gilbertson, R.; Iannaccone, S.; Iannaccone, P.; Walterhouse, D. Defining a role for Sonic hedgehog pathway activation in desmoplastic medulloblastoma by identifying GLI1 target genes. Int. J. Cancer 2009, 124, 109–119. [CrossRef] [PubMed]
50. Zhu, H.; Lo, H.W. The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases. Curr. Genomics 2010, 11, 238–245. [CrossRef] [PubMed]
51. Dianov, G.L.; Hubscher, U. Mammalian base excision repair: The forgotten archangel. Nucleic Acids Res. 2013, 41, 3483–3490. [CrossRef] [PubMed]
52. David, S.S.; O’Shea, V.L.; Kundu, S. Base-excision repair of oxidative DNA damage. Nature 2007, 447, 941–950. [CrossRef] [PubMed]
53. Helleday, T.; Petermann, E.; Lundin, C.; Hodgson, B.; Sharma, R.A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 2008, 8, 193–204. [CrossRef] [PubMed]
54. Taverna, P.; Hwang, H.S.; Schupp, J.E.; Radivoyevitch, T.; Session, N.N.; Reddy, G.; Zarling, D.A.; Kinsella, T.J. Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization. Cancer Res. 2003, 63, 838–846. [PubMed]
55. Lieber, M.R.; Ma, Y.; Pannicke, U.; Schwarz, K. The mechanism of vertebrate nonhomologous DNA end joining and its role in V(D)J recombination. DNA Repair 2004, 3, 817–826. [CrossRef] [PubMed]
56. Mazumdar, T.; Devecchio, J.; Agyeman, A.; Shi, T.; Houghton, J.A. Blocking Hedgehog survival signaling at the level of the GLI genes induces DNA damage and extensive cell death in human colon carcinoma cells. Cancer Res. 2011, 71, 5904–5914. [CrossRef] [PubMed]
57. Wu, X.Y.; Che, J.; Sun, K.K.; Shen, X.J.; Yang, D.; Zhong, N.; Zhao, H. Cyclopamine increases the radiosensitivity of human pancreatic cancer cells by regulating the DNA repair signal pathway through an epidermal growth factor receptordependent pathway. Mol. Med. Rep. 2013, 8, 979–983. [PubMed]
58. Aparicio, T.; Baer, R.; Gautier, J. DNA double-strand break repair pathway choice and cancer. DNA Repair 2014, 19, 169–175. [CrossRef] [PubMed]
59. Thompson, L.H.; Schild, D. Recombinational DNA repair and human disease. Mutat. Res. 2002, 509, 49–78. [CrossRef]
60. Liu, C.; Srihari, S.; Cao, K.A.; Chenevix-Trench, G.; Simpson, P.T.; Ragan, M.A.; Khanna, K.K. A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. Nucleic Acids Res. 2014, 42, 6106–6127. [CrossRef] [PubMed]
61. Burma, S.; Chen, B.P.; Chen, D.J. Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair 2006, 5, 1042–1048. [CrossRef] [PubMed]
62. Deans, A.J.; West, S.C. DNA interstrand crosslink repair and cancer. Nat. Rev. Cancer 2011, 11, 467–480. [CrossRef] [PubMed]
63. Wang, L.C.; Gautier, J. The Fanconi anemia pathway and ICL repair: Implications for cancer therapy. Crit. Rev. Biochem. Mol. Biol. 2010, 45, 424–439. [CrossRef] [PubMed]
64. Geiman, T.M.; Durum, S.K.; Muegge, K. Characterization of gene expression, genomic structure, and chromosomal localization of Hells (Lsh). Genomics 1998, 54, 477–483. [CrossRef] [PubMed]
65. Shi, T.; Mazumdar, T.; Devecchio, J.; Duan, Z.H.; Agyeman, A.; Aziz, M.; Khanna, K.K. cDNA microarray gene expression profiling of hedgehog signaling pathway inhibition in human colon cancer cells. PLoS ONE 2010. [CrossRef] [PubMed]
66. Leonard, J.M.; Ye, H.; Wetmore, C.; Karnitz, L.M. Sonic Hedgehog signaling impairs ionizing radiation-induced checkpoint activation and induces genomic instability. J. Cell Biol. 2008, 183, 385–391. [CrossRef] [PubMed]
67. Olson, E.; Nievera, C.J.; Lee, A.Y.; Chen, L.; Wu, X. The Mre11-Rad50-Nbs1 complex acts both upstream and downstream of ataxia telangiectasia mutated and Rad3-related protein (ATR) to regulate the S-phase checkpoint following UV treatment. J. Biol. Chem. 2007, 282, 22939–22952. [CrossRef] [PubMed]
68. Wu, L.; Luo, K.; Lou, Z.; Chen, J. MDC1 regulates intra-S-phase checkpoint by targeting NBS1 to DNA double-strand breaks. Proc. Natl. Acad. Sci. USA 2008, 105, 11200–11205. [CrossRef] [PubMed]
69. Williams, G.J.; Williams, R.S.; Williams, J.S.; Moncalian, G.; Arvai, A.S.; Limbo, O.; Khanna, K.K. ABC ATPase signature helices in Rad50 link nucleotide state to Mre11 interface for DNA repair. Nat. Struct. Mol. Biol. 2011, 18, 423–431. [CrossRef] [PubMed]
70. Agyeman, A.; Mazumdar, T.; Houghton, J.A. Regulation of DNA damage following termination of Hedgehog (HH) survival signaling at the level of the GLI genes in human colon cancer. Oncotarget 2012, 3, 854–868. [PubMed]
71. Glassner, B.J.; Rasmussen, L.J.; Najarian, M.T.; Posnick, L.M.; Samson, L.D. Generation of a strong mutator phenotype in yeast by imbalanced base excision repair. Proc. Natl. Acad. Sci. USA 1998, 95, 9997–10002. [CrossRef] [PubMed]
72. Drotschmann, K.; Aronshtam, A.; Fritz, H.J.; Marinus, M.G. The Escherichia coli MutL protein stimulates binding of Vsr and MutS to heteroduplex DNA. Nucleic Acids Res. 1998, 26, 948–953. [CrossRef] [PubMed]
73. Lieb, M.; Rehmat, S.; Bhagwat, A.S. Interaction of MutS and Vsr: Some dominant-negative mutS mutations that disable methyladenine-directed mismatch repair are active in very-short-patch repair. J. Bacteriol. 2001, 183, 6487–6490. [CrossRef] [PubMed]
74. Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 495–516. [CrossRef] [PubMed]
75. Nolan-Stevaux, O.; Lau, J.; Truitt, M.L.; Chu, G.C.; Hebrok, M.; Fernandez-Zapico, M.E.; Hanahan, D. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes. Dev. 2009, 23, 24–36. [CrossRef] [PubMed]
76. Olive, K.P.; Jacobetz, M.A.; Davidson, C.J.; Gopinathan, A.; McIntyre, D.; Honess, D.; Madhu, B.; Goldgraben, M.A.; Caldwell, M.E.; Allard, D et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324, 1457–1461. [CrossRef] [PubMed]
77. Singh, B.N.; Fu, J.; Srivastava, R.K.; Shankar, S. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: Molecular mechanisms. PLoS ONE 2011, 6, e27306. [CrossRef] [PubMed]
78. Liao, X.; Siu, M.K.; Au, C.W.; Wong, E.S.; Chan, H.Y.; Ip, P.P.; Ngan, H.Y.; Cheung, A.N. Aberrant activation of hedgehog signaling pathway in ovarian cancers: Effect on prognosis, cell invasion and differentiation. Carcinogenesis 2009, 30, 131–140. [CrossRef] [PubMed]
79. Chen, X.; Horiuchi, A.; Kikuchi, N.; Osada, R.; Yoshida, J.; Shiozawa, T.; Konishi, I. Hedgehog signal pathway is activated in ovarian carcinomas, correlating with cell proliferation: It’s inhibition leads to growth suppression and apoptosis. Cancer Sci. 2007, 98, 68–76. [CrossRef] [PubMed]
80. Wang, K.; Pan, L.; Che, X.; Cui, D.; Li, C. Gli1 inhibition induces cell-cycle arrest and enhanced apoptosis in brain glioma cell lines. J. Neurooncol. 2010, 98, 319–327. [CrossRef] [PubMed]
81. Chandra, V.; Das, T.; Gulati, P.; Biswas, N.K.; Rote, S.; Chatterjee, U. Hedgehog signaling pathway is active in GBM with GLI1 mRNA expression showing a single continuous distribution rather than discrete high/low clusters. PLoS ONE 2015, 10, e0116390. [CrossRef] [PubMed]
82. Bigelow, R.L.; Chari, N.S.; Unden, A.B.; Spurgers, K.B.; Lee, S.; Roop, D.R.; Toftgard, R.; McDonnell, T.J. Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1. J. Biol. Chem. 2004, 279, 1197–1205. [CrossRef] [PubMed]
83. Sims-Mourtada, J.; Izzo, J.G.; Ajani, J.; Chao, K.S. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 2007, 26, 5674–5679. [CrossRef] [PubMed]
84. Amable, L.; Fain, J.; Gavin, E.; Reed, E. Gli1 contributes to cellular resistance to cisplatin through altered cellular accumulation of the drug. Oncol Rep. 2014, 32, 469–474. [CrossRef] [PubMed]
85. Moukharskaya, J.; Verschraegen, C. Topoisomerase 1 inhibitors and cancer therapy. Hematol./Oncol. Clin. N. Am. 2012, 26, 507–525. [CrossRef] [PubMed]
86. Chen, A.Y.; Chen, P.M.; Chen, Y.J. DNA topoisomerase I drugs and radiotherapy for lung cancer. J. Thorac. Dis. 2012, 4, 390–397. [PubMed]
87. Pommier, Y. DNA topoisomerase I inhibitors: Chemistry, biology, and interfacial inhibition. Chem. Rev. 2009, 109, 2894–2902. [CrossRef] [PubMed]
88. Tripathi, K.; Mani, C.; Barnett, R.; Nalluri, S.; Bachaboina, L.; Rocconi, R.P.; Athar, M.; Owen, L.B.; Palle, K. Gli1 protein regulates the S-phase checkpoint in tumor cells via Bid protein, and its inhibition sensitizes to DNA topoisomerase 1 inhibitors. J. Biol. Chem. 2014, 289, 31513–31525. [CrossRef] [PubMed]
89. Infante, P.; Mori, M.; Alfonsi, R.; Ghirga, F.; Aiello, F.; Toscano, S.; Ingallina, C.; Siler, M.; Cucchi, D.; Po, A et al. Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors. EMBO J. 2015, 34, 200–217. [CrossRef] [PubMed]
90. Tang, Y.; Gholamin, S.; Schubert, S.; Willardson, M.I.; Lee, A.; Bandopadhayay, P.; Bergthold, G.; Masoud, S.; Nguyen, B.; Vue, N et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat. Med. 2014, 20, 732–740. [CrossRef] [PubMed]
91. Thayer, S.P.; di Magliano, M.P.; Heiser, P.W.; Nielsen, C.M.; Roberts, D.J.; Lauwers, G.Y.; Qi, Y.P.; Gysin, S.; Fernandez-del Castillo, C.; Yajnik, V et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425, 851–856. [CrossRef] [PubMed]
92. Dierks, C.; Grbic, J.; Zirlik, K.; Beigi, R.; Englund, N.P.; Guo, G.R.; Veelken, H.; Engelhardt, M.; Mertelsmann, R.; Kelleher, J.F et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat. Med. 2007, 13, 944–951. [CrossRef] [PubMed]
93. Berman, D.M.; Karhadkar, S.S.; Maitra, A.; Montes de Oca, R.; Gerstenblith, M.R.; Briggs, K.; Parker, A.R.; Shimada, Y.; Eshleman, J.R.; Watkins, D.N et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003, 425, 846–851. [CrossRef] [PubMed]
94. Hidalgo, M.; Maitra, A. The hedgehog pathway and pancreatic cancer. N. Engl. J. Med. 2009, 361, 2094–2096. [CrossRef] [PubMed]
95. Karhadkar, S.S.; Bova, G.S.; Abdallah, N.; Dhara, S.; Gardner, D.; Maitra, A.; Isaacs, J.T.; Berman, D.M.; Beachy, P.A. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004, 431, 707–712. [CrossRef] [PubMed]
96. Chandra, A.; Lin, T.; Zhu, J.; Tong, W.; Huo, Y.; Jia, H.; Zhang, Y.; Liu, X.S.; Cengel, K.; Xia, B et al. PTH1–34 blocks radiation-induced osteoblast apoptosis by enhancing DNA repair through canonical Wnt pathway. J. Biol. Chem. 2015, 290, 157–167. [CrossRef] [PubMed]
97. Kim, M.R.; Lee, J.; An, Y.S.; Jin, Y.B.; Park, I.C.; Chung, E.; Shin, I.; Barcellos-Hoff, M.H.; Yi, J.Y. TGFbeta1 protects cells from gamma-IR by enhancing the activity of the NHEJ repair pathway. Mol. Cancer Res. 2015, 13, 319–329. [CrossRef] [PubMed]
98. Yu, Y.; Wang, Y.; Ren, X.; Tsuyada, A.; Li, A.; Liu, L.J.; Wang, S.E. Context-dependent bidirectional regulation of the MutS homolog 2 by transforming growth factor beta contributes to chemoresistance in breast cancer cells. Mol. Cancer Res. 2010, 8, 1633–1642. [CrossRef] [PubMed]